Palvella Therapeutics adds Matt Pauls to its board of directors Jun 30, 2026 07:30AM
Palvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.D., M.B.A., to Board of Directors Jun 30, 2026 07:30AM
Palvella files first NDA module for rare lymphatic malformation drug Jun 29, 2026 07:30AM
Palvella Therapeutics Submits First Module of Rolling New Drug Application to FDA for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations Jun 29, 2026 07:30AM
FDA grants rolling review for Palvella's rapamycin NDA for rare condition Jun 22, 2026 07:30AM
View Older Stories

Jun 22, 2026 07:30AM FDA Grants Rolling Review of Palvella’s QTORIN™ Rapamycin NDA for Microcystic Lymphatic Malformations
Jun 3, 2026 07:30AM Palvella Therapeutics completes FDA pre-NDA meeting for QTORIN rapamycin
Jun 3, 2026 07:30AM Palvella Therapeutics Announces Completion of FDA Pre-NDA Meeting for QTORIN™ Rapamycin in Microcystic Lymphatic Malformations
Jun 2, 2026 07:30AM Palvella Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026
May 27, 2026 07:31AM Palvella Therapeutics receives Yale-licensed patent for QTORIN pitavastatin
May 27, 2026 07:30AM Palvella Therapeutics Strengthens QTORIN™ Pitavastatin Intellectual Property with Yale-Licensed U.S. Patent Providing Protection into 2043
May 21, 2026 07:30AM Palvella Therapeutics Named Healthcare & Life Sciences Company of the Year at the Philadelphia Alliance for Capital and Technologies (PACT) Ecosystem Awards
May 20, 2026 04:30PM Palvella presents positive data for QTORIN rapamycin at vascular congress
May 20, 2026 04:30PM Palvella Therapeutics Presents New SELVA and TOIVA Data at the 2026 International Society for the Study of Vascular Anomalies World Congress Supporting QTORIN™ Rapamycin as a Potential First-in-Dise
May 15, 2026 07:30AM Palvella reports positive bleeding results from QTORIN rapamycin trial
May 15, 2026 07:30AM Palvella reports positive bleeding results from rapamycin trial
May 15, 2026 07:30AM Palvella Therapeutics Announces New Data from the Phase 2 TOIVA Trial of QTORIN™ Rapamycin in Cutaneous Venous Malformations Presented at the 83rd Annual Meeting of the Society for Investigative Der
May 13, 2026 07:30AM Palvella Therapeutics moves to NASDAQ Global Market
May 13, 2026 07:30AM Palvella Therapeutics Announces Uplisting to the Nasdaq Global Market
May 7, 2026 07:30AM Palvella Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 4, 2026 07:30AM Palvella Therapeutics begins Phase 2 trial for rare skin condition
May 4, 2026 07:30AM Palvella Therapeutics Announces First Patients Dosed in Phase 2 LOTU Trial of Fast Track-Designated QTORIN™ Rapamycin for Clinically Significant Angiokeratomas
Apr 30, 2026 07:30AM Palvella Therapeutics to Host First Quarter 2026 Financial Results and Corporate Update Conference Call on May 7, 2026
Apr 20, 2026 07:30AM Palvella to present QTORIN rapamycin study results at vascular congress
Apr 20, 2026 07:30AM Palvella Therapeutics to Present QTORIN™ Rapamycin Results from Phase 3 SELVA and Phase 2 TOIVA Studies at the International Society for the Study of Vascular Anomalies World Congress 2026
Apr 13, 2026 07:30AM Palvella appoints dermatologist John Doux to board of directors
Apr 13, 2026 07:30AM Palvella Therapeutics Appoints John D. Doux, M.D., M.B.A., Dermatologist and Recognized Leader in Rare Skin Diseases, to Board of Directors
Apr 7, 2026 12:26PM Palvella Therapeutics names Kent Taylor sales chief
Apr 7, 2026 07:30AM Palvella Therapeutics Appoints Accomplished Commercial Leader Kent Taylor as Senior Vice President of Sales
Mar 31, 2026 07:30AM Palvella Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update
Mar 30, 2026 07:31AM Palvella publishes research on lymphatic malformation subtypes
Mar 30, 2026 07:30AM Palvella Therapeutics Announces Scientific Publication in Journal of Vascular Anomalies Highlighting the Infiltrative Growth and Therapeutic Challenges of Microcystic Lymphatic Malformations
Mar 27, 2026 10:30AM Palvella Therapeutics presents research at dermatology meeting
Mar 27, 2026 10:30AM Palvella Therapeutics Highlights Continued Progress Across Rare Skin Disease Pipeline with Two Poster Presentations at the 2026 American Academy of Dermatology Annual Meeting
Mar 24, 2026 09:50AM Palvella Therapeutics hires Jennifer McDonough as senior VP
Mar 24, 2026 07:30AM Palvella Therapeutics to Host Full Year 2025 Financial Results Conference Call and Provide a Corporate Update on March 31, 2026
Mar 23, 2026 07:30AM Palvella hires Jennifer McDonough as market access VP
Mar 23, 2026 07:30AM Palvella Therapeutics Strengthens Leadership Team with Appointment of Rare Disease Commercial Leader Jennifer J. McDonough as Senior Vice President of Market Access and Patient Services
Mar 23, 2026 07:30AM Palvella Therapeutics Strengthens Leadership Team with Appointment of Rare Disease Commercial Leader Jennifer J. McDonough as Senior Vice President of Market Access and Patient Services
Mar 16, 2026 07:31AM Palvella receives European patent for QTORIN rapamycin formulation
Mar 16, 2026 07:30AM Palvella Therapeutics Announces Issuance of European Patent Covering Anhydrous Compositions of Rapamycin
Mar 10, 2026 07:31AM Palvella launches disease awareness campaign for rare lymphatic condition
Mar 10, 2026 07:30AM Palvella Therapeutics Launches "BEYOND mLM" Disease Awareness Campaign for Microcystic Lymphatic Malformations in Collaboration with Leading Lymphatic, Vascular, and Dermatology Nonprofit Or
Feb 24, 2026 06:30AM Palvella Therapeutics reports positive phase 3 trial results for rare disease
Feb 24, 2026 06:30AM Palvella Therapeutics Announces Positive Topline Results from Phase 3 SELVA Clinical Study of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) in Microcystic Lymphatic Malformations
Feb 23, 2026 05:00PM Palvella schedules call to discuss Phase 3 trial results for skin gel
Feb 23, 2026 05:00PM Palvella Therapeutics to Host Conference Call to Discuss Topline Results from Phase 3 SELVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) in Microcystic Lymphatic Malf
Feb 2, 2026 07:30AM Palvella Therapeutics publishes systematic review on statin use in porokeratosis
Feb 2, 2026 07:30AM Palvella Therapeutics Announces Scientific Publication in Clinical and Experimental Dermatology Highlighting a Systematic Review of Real-World Statin Evidence and Persistent Treatment Gaps Resulting f
Jan 9, 2026 07:30AM Palvella plans March 2026 data readout for rare skin disease drug
Jan 9, 2026 07:30AM Palvella Therapeutics Provides Corporate Update and 2026 Outlook: Advancing a Late Clinical-Stage Pipeline and Platform to Address Multiple Serious, Rare Skin Diseases and Vascular Malformations with
Jan 7, 2026 07:30AM Palvella Therapeutics Strengthens Leadership Team with Appointment of Veteran Medical Affairs Leader Vimal Patel, PharmD, as Senior Vice President of Medical Affairs
Dec 16, 2025 07:30AM Palvella Therapeutics receives FDA fast track designation for angiokeratoma treatment
Dec 16, 2025 07:30AM Palvella Therapeutics Granted FDA Fast Track Designation for QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Angiokeratomas
Dec 15, 2025 06:00AM Palvella reports positive Phase 2 results for rare skin disease treatment
View Older Stories